曲美他嗪治疗老年冠心病伴慢性心力衰竭的疗效观察  

Observation of the Effects of Trimetazidine in the Aged with Coronary Heart Disease and Heart Failure

作　　者：张惠芳[1] 牛瑞刚[1] 刘金霞[1] 刘大成[1] 王晨晨[1] 刘树静[1] 

机构地区：[1]北京市房山区第一医院心内科,北京102488

出　　处：《中国医药导刊》2010年第7期1194-1195,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨曲美他嗪治疗老年冠状动脉粥样硬化性心脏病(简称冠心病)伴慢性心力衰竭的疗效。方法:80例患者随机分为常规治疗组和曲美他嗪组。常规治疗组为应用硝酸酯类、利尿剂、血管紧张转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB),β受体阻滞剂,洋地黄制剂等进行常规治疗;曲美他嗪组为常规治疗组的基础上加用曲美他嗪20mg,每天3次口服,治疗6个月,观察治疗前后患者临床情况及超声心动图指标的变化。结果:治疗后两组心功能均明显改善,心排血量(CO)、每搏量(SV)、射血分数(LVEF)增加,左室舒张末容积(LVEDV)减少(P<0.05,P<0.01),差异有统计学意义,但曲美他嗪组疗效优于常规组,两组比较差异有统计学意义(P<0.05)。结论:曲美他嗪治疗老年冠心病伴慢性心衰安全、有效。Objective：To evaluate the effects of trimetazidine （TMZ） in patients who suffered from coronary atheroselerosis heart disease complicated with heart failure.Methods：80 selected aged patients were randomly divided into TMZ group and control group.TMZ group received.Trimetazidine （60 mg/d） and routine medications for 6 months,while control group only received routine medications during the same period.Agents administered in control group were Nitrates,Diuretics,Angiotensin converting enzyme inhibitor （ACEI）,Blocker of angiotensin Angiotensin Ⅱ receptor （ARB）,13-receptor antagonist,and digitalis,etc.Observing and comparing the clinical manifestation of patients and echocardiogram outcomes before and after 6 months＇ medication.Results：After 6 months treatment,in both groups cardiac output, stroke volume ejection fraction increased dramatically and left ventricular end diastolic volume decreased （P〈0.05,P〈0.01）,but index improvement in TMZ group were more obvious.There was significant difference between TMZ group and control group （P〈0.05）.Conclusion：TMZ was safe and effective in the aged with coronary heart disease and heart failure.

关 键 词：曲美他嗪 冠状动脉粥样硬化性心脏病 心力衰竭 

分 类 号：R541.4[医药卫生—心血管疾病]